Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05016895
Other study ID # 1743615
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 27, 2021
Est. completion date February 28, 2024

Study information

Verified date February 2024
Source FHI 360
Contact Lisa Dulli, PhD
Phone 9193213542
Email ldulli@fhi360.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

REACH2 is a three-year implementation research study designed to examine the implementation through a mass drug administration platform of bi-annual single-dose azithromycin to reduce child mortality among children ages 1 to 11 months who reside in high child mortality settings.


Description:

The aim of the study is to provide the government of Côte d'Ivoire and other stakeholders the information needed to understand what is required to bring bi-annual mass drug administration (MDA) of single-dose azithromycin for children ages 1 to 11 months in high child mortality settings to scale using the existing MDA platform used for trachoma and other neglected tropical diseases. Design: The serial cross-sectional study will be carried out in 19 health districts in coordination with the trachoma MDAs over the course of three years. The intervention under study will involve a public health campaign of bi-annual distribution of single-dose azithromycin, including: 1. Expanded coverage with azithromycin during annual trachoma MDAs to children 1-5 months of age when delivered at the same time as the annual trachoma MDA, which already covers children 6-11 months, followed by 2. Stand-alone MDAs targeting children 1 to 11 months delivered at the approximately 6-month interval between annual trachoma MDAs, or bi-annually in areas where the annual trachoma MDAs are phased out. To study scale up of these intervention activities, the investigators will systematically collect data, guided by the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) implementation science framework. Data collection activities will involve: 1. Analyses of routine monitoring, process, and adverse drug reaction data from the trachoma MDA platform into which the REACH activities are being integrated 2. Periodic, cross-sectional, post-MDA surveys to verify coverage and examine exposure to project information/messaging 3. Qualitative data collection through in-depth interviews (IDI) and/or focus group discussions (FGD) with parents or primary caregivers of children ages 1 to 11 months in the 19 health districts, and district-level MDA implementers to explore issues of acceptability, communication, challenges and areas for improvement in implementation. Further, after the first round of the annual trachoma MDA scheduled to take place in July 2021, a round of focus groups will be carried out with parents of children ages 1-11 months and local implementers to inform message development for the public health campaign.


Recruitment information / eligibility

Status Recruiting
Enrollment 140000
Est. completion date February 28, 2024
Est. primary completion date February 28, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Month to 11 Months
Eligibility Inclusion Criteria: - Ages 1 to 11 months - Resident in targeted community Exclusion Criteria: - Children below 3.0 kg (3rd centile for healthy 1-month old infants in the WHO growth charts) - Appears seriously ill at the time of the MDA (per the CDD's assessment) - Unable to swallow liquid delivered through a needle-less syringe because of physical limitations - Known allergy to macrolides, including azithromycin, based on the primary caregiver's report of prior adverse reaction to medication likely to be a macrolide - prior allergic reaction to medication likely to be a macrolide

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Single-dose azithromycin
Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.

Locations

Country Name City State
Côte D'Ivoire Community-based service delivery Abidjan

Sponsors (2)

Lead Sponsor Collaborator
FHI 360 Ministère de la Santé et de l´Hygiène Publique (Côte d'Ivoire)

Country where clinical trial is conducted

Côte D'Ivoire, 

Outcome

Type Measure Description Time frame Safety issue
Primary % of eligible population covered by intervention coverage of the intervention's target population (reach) with azithromycin in targeted health districts three years
Primary Infant mortality rate Rate of child deaths among children under 1 year of age per 1,000 population three years
Primary Implementation fidelity Proportion of intervention activities are carried out as planned three years
Secondary Cost of the program as a whole Program costs will be calculated based on the following inputs: personnel, supplies/recurrent goods, capital goods, travel/transport, space, services, and training three years
Secondary Cost per child treated Program costs per child treated three years
Secondary Cost per death averted Program costs per death averted three years
See also
  Status Clinical Trial Phase
Recruiting NCT04716712 - Infant Mortality Reduction by the Mass Administration of Azithromycin Phase 4
Completed NCT02943681 - A Second Dose of Measles Vaccine (MV) in the Second Year of Life N/A
Completed NCT02233127 - Birth Cohort in Rahimyar Khan, Pakistan N/A
Completed NCT03676751 - MORDOR II Burkina Faso: Longitudinal Trial Phase 4
Completed NCT04617626 - Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire N/A
Completed NCT03367832 - South African Paediatric Surgical Outcomes Study (SAPSOS) N/A
Recruiting NCT00656591 - Community-Based Interventions for Infant Health in Nepal Phase 1
Recruiting NCT04235816 - Improving Care Through Azithromycin Research for Infants in Africa Phase 3
Completed NCT01571765 - MNCH Programming in Southwest Uganda Maternal and Child Health In Bushenyi and Rubirizi Districts, UGANDA N/A